Effect of The Rs-10 Radioprotector on Protein-Steroid Interaction in Irradiated Animals with Biphasic Adrenocortical Response to Irradiation

Nadezhda Omelchuk

doi:10.48161/qaj.v3n4a163

Authors

Nadezhda Omelchuk Department of Clinical Laboratory Diagnostics, Faculty of Continuing Medical Education, Peoples' Friendship University of Russia, Russia

DOI:

https://doi.org/10.48161/qaj.v3n4a163

Abstract

The article is devoted to the influence of RS-10 radioprotector on the protein-steroid interaction in irradiated animals. Introduction. Increasing threats to the radiation safety of the population is now causing the need for comprehensive studies of the anti-beam properties of chemical radioprotectors. The aim of the study is to study the effect of the RS-10 radioprotector on protein-steroid interaction in irradiated guinea pigs with biphasic adrenocortical response to irradiation. Study methods: experiments were conducted on 146 guinea pigs weighing 300-350 g, which were exposed to total ƴ radiation at a dose of 3.5 Gy and 4.5 Gy at a dose rate of 5.76 Gy/min, which caused them radiation disease of II and III severity. Experimental animals were injected intraperitoneally with RS-10 (chitosan bitartrate) 15 minutes before irradiation. Control animals were administered an equal volume of saline. The total plasma content of 11-oxycorticosteroids (11-OKS) was determined by the fluorometric method of Guillemin et al. in the author's modification. The binding capacity of corticosteroid binding globulin (CSG) was determined by gel filtration of De Moor at al. in the author's modification. Conclusions. Prophylactic administration of RS-10 to irradiated animals with a two-phase adreno-cortical reaction to radiation causes a later onset of secondary hypercorticism in the midst of radiation sickness in animals. Prophylactic administration of RS-10 before irradiation reduces the level of free hormone and leads to a decrease in hypercorticism, increasing the reserve capabilities of the binding ability of the CSG at the height of radiation sickness. A leading role in the mechanism of reducing affected hypercorticism under protective conditions has a lesser degree of impairment of the binding capacity of the CSG, rather than a change in the total level of 11-OKS in the blood.

Downloads

Download data is not yet available.

References

L. M. Rozhdestvensky, “The Past and Future of Radiobiology of Anti-Radiation Agents at the Institute of Biophysics of the USSR Ministry of Health,” Medical Radiology and Radiation Safety, vol. 5, pp. 80-89, 2016.

R. U. Khabriev, E. N. Mingazova, V. V. Sidorov, S. A. Gureev, and M. M. Yusupova, “Biocompatible Protective Drugs against Radiation Exposure: A Modern View of the Problem,” Remedium, vol. 4, pp. 3-8, 2021.

V. Kuruba, and P. Gollapalli, “Natural Radioprotectors and their Impact on Cancer Drug Discovery,” Radiation Oncology, vol. 36, no. 4, pp. 265-275, 2019.

E. A. Domina, “Protivoluchevye SREDSTVA: Klassifikatsiia i Mekhanizmy [Anty Radiation Means: Classification and Mechanisms],” Problemy Radiatsiinoi Medytsyny ta Radiobiolohii, vol. 20, pp. 42-54, 2015.

M. V. Vasin, “Classification of Anti-Radiation Agents as a Reflection of the Current State and Prospects for the Development of Radiation Pharmacology,” Radiation Biology. Radioecology, vol. 53, no. 5, pp. 459-467, 2013.

V. I. Legeza, and V. G. Vladimirov, “New Classification of Preventive Anti-radiation Agents,” Radiation Biology. Radioecology, vol. 8, no. 3, pp. 416-425, 1998.

L. M. Rozhdestvensky, “Classification of Anti-Radiation Agents in the Aspect of their Pharmacological Signal and Conjugacy with the Stage of Development of Radiation Damage,” Radiation Biology. Radioecology, vol. 57, no. 2, pp. 118-135, 2017.

L. M. Rozhdestvensky, “Problems of Development of Domestic Anti-Radiation Agents in the Crisis Period: Search for Relevant Directions of Development,” Radiation Biology. Radioecology, vol. 60, no. 3, pp. 279-290, 2020.

I. Kashiwakura, “Overview of Radiation-Protective Agent Research and Prospects for the Future,” Japanese Journal of Health Physics, vol. 52, no. 4, pp. 285-295, 2017.

M. I. Koukourakis, “Radiation Damage and Radioprotectants: New Concepts in the Era of Molecular Medicine,” The British Journal of Radiology, vol. 85, no. 1012, pp. 313-330, 2012.

L. M. Rozhdestvensky, M. I. Fedotova, A. I. Romanov, and O. I. Belousova, “On the Ways of Implementation and Mechanisms of the Anti-Radiation Action of RS-10, Mercamina and Mexamina,” Radiation Biology. Radioecology, vol. 57, no. 5, pp. 540-544, 2017.

M. Zivkovic Radojevic, N. Milosavljevic, T. B. Miladinovic, S. Janković, and M. Folic, “Review of Compounds that Exhibit Radioprotective and/or Mitigatory Effects after Application of Diagnostic or Therapeutic Ionizing Radiation,” International Journal of Radiation Biology, vol. 99, no. 4, pp. 594-603, 2023. https://doi.org/10.1080/09553002.2022.2110308

M. Adnan, A. Rasul, M. A. Shah, G. Hussain, M. Asrar, A. Riaz, et al., “Radioprotective Role of Natural Polyphenols: From Sources to Mechanisms,” Anti-Cancer Agents in Medicinal Chemistry, vol. 22, no. 1, pp. 30-39, 2022. https://doi.org/10.2174/1871520621666210419095829

P. Marino, G. Pepe, M. G. Basilicata, V. Vestuto, S. Marzocco, G. Autore, et al., “Potential Role of Natural Antioxidant Products in Oncological Diseases,” Antioxidants, vol. 12, no. 3, art. no. 704, 2023. https://doi.org/10.3390/antiox12030704

T. L. Lim, R. A. Pietrofesa, E. Arguiri, C. Koumenis, S. Feigenberg, C. B. Simone, et al., “Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer,” Journal of Alternative and Complementary Medicine, vol. 27, no. 10, pp. 824-831, 2021. https://doi.org/10.1089/acm.2020.0542

C. M. Anderson, C. M. Lee, D. Saunders, A. E. Curtis, N. E. Dunlap, C. Nangia, et al., “Two-Year Tumor Outcomes of a Phase 2B, Randomized, Double-Blind Trial of Avasopasem Manganese (GC4419) Versus Placebo to Reduce Severe Oral Mucositis Owing to Concurrent Radiation Therapy and Cisplatin for Head and Neck Cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 114, no. 3, pp. 416–421, 2022. https://doi.org/10.1016/j.ijrobp.2022.06.063

V. G. Vladimirov, and I. I. Krasilnikov, “On Some Results and Prospects for the Development of Preventive Radiation Pharmacology,” Reviews on Clinical Pharmacology and Drug Therapy, vol. 9, no. 1, pp. 44-50, 2011.

Yu. V. Kozina, R. A. Zukov, E. V. Slepov, and E. V. Kozina, “Role of Radioprotectors and Immunotropes in the Prevention of Radiation Reactions and Complications,” Effective Pharmacotherapy, vol. 17, no. 2, pp. 50-57, 2021.

S. M. Bentzen, and A. Trotti, “Evaluation of Early and Late Toxicities in Chemoradiation Trials,” Journal of Clinical Oncology, vol. 25, pp. 4096-4103, 2007.

N. N. Omelchuk, “Binding Ability of Plasma Corticosteroid-Binding Globulin as a Mechanism for Increasing the Free Fraction of Hormone in the Pathogenesis of Acute Radiation Sickness,” Radiation and Risk, vol. 31, no. 3, pp. 139-146, 2022.

P. D. Horizons, V. A. Razorenova, M. F. Sbitneva, and I. E. Andrianova, “Radioprotective and Therapeutic Efficacy of the Drug RS-10 in Experiments on Dogs,” Radiation Biology. Radioecology, vol. 57, no. 5, pp. 529-539, 2017.

S. A. Davydova, “Results of Commission Trials of the Drug RS-10 as a Means of Early Treatment of Acute Radiation Sickness,” in L. A. Ilyin, and A. S. Samoilov (Eds.), Selected materials of the "Bulletin of Radiation Medicine", 2016, pp. 571-582.